BNT162b2 Against COVID-19-Associated Emergency Department and Urgent Care Visits Among Children 5-11 Years of Age: A Test Negative Design

被引：3

作者：

Tartof, Sara Y. ^{[1
,2
]}

Frankland, Timothy B. ^{[3
]}

Puzniak, Laura ^{[4
]}

Slezak, Jeff M. ^{[1
]}

Hong, Vennis ^{[1
]}

Takhar, Harpreet ^{[1
]}

Ogun, Oluwaseye A. ^{[1
]}

Simmons, Sarah ^{[1
]}

Xie, Fagen ^{[1
]}

Zamparo, Joann ^{[4
]}

Ackerson, Bradley K. ^{[5
]}

Jodar, Luis ^{[4
]}

McLaughlin, John M. ^{[4
]}

机构：

[1] Kaiser Permanente Southern Calif, Dept Res & Evaluat, 1000 S Los Robles,2nd Floor, Pasadena, CA 91101 USA

[2] Kaiser Permanente Bernard J Tyson Sch Med, Dept Hlth Syst Sci, Pasadena, CA USA

[3] Kaiser Permanente Hawaii Ctr Integrated Hlth Care, Honolulu, HI USA

[4] Pfizer Inc, Collegeville, PA USA

[5] Southern Calif Permanente Med Grp, Harbor City, CA USA

来源：

JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY | 2023年 / 12卷 / 03期

关键词：

BNT162b2; booster; COVID-19; delta; effectiveness; Kaiser Permanente; omicron; pediatric; real-world; SARS-CoV-2; test-negative; United States; VACCINE;

D O I：

10.1093/jpids/piad005

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

In a 1:1 matched test-negative design among 5- to 11-year-olds in the Kaiser Permanente Southern California health system (n = 3984), BNT162b2 effectiveness against the omicron-related emergency department or urgent care encounters was 60% [95%CI: 47-69] <3 months post-dose-two and 28% [8-43] after >= 3 months. A booster improved protection to 77% [53-88].

引用

页码：177 / 179

页数：3

共 35 条

[21] Safety and health care utilization following COVID-19 vaccination (BNT162b2) among children and youth with juvenile idiopathic arthritis and inflammatory bowel disease: A population-based study
Lee, Jennifer J. Y.
Bernatsky, Sasha
Benchimol, Eric, I
Kwong, Jeffrey C.
Li, Qing
Yeung, Rae S. M.
Widdifield, Jessica
PAEDIATRICS & CHILD HEALTH, 2025,
[22] Effectiveness of BNT162b2 COVID-19 primary series vaccination in children aged 5-17 years in the United States: a cohort study
Ogilvie, Rachel P.
Layton, J. Bradley
Lloyd, Patricia C.
Jiao, Yixin
Djibo, Djeneba Audrey
Wong, Hui Lee
Gruber, Joann F.
Parambi, Ron
Deng, Jie
Miller, Michael
Song, Jennifer
Weatherby, Lisa B.
Peetluk, Lauren
Lo, An-Chi
Matuska, Kathryn
Wernecke, Michael
Bui, Christine L.
Clarke, Tainya C.
Cho, Sylvia
Bell, Elizabeth J.
Yang, Grace
Amend, Kandace L.
Forshee, Richard A.
Anderson, Steven A.
McMahill-Walraven, Cheryl N.
Chillarige, Yoganand
Anthony, Mary S.
Seeger, John D.
Shoaibi, Azadeh
BMC PEDIATRICS, 2024, 24 (01)
[23] Sex differences in symptoms following the administration of BNT162b2 mRNA COVID-19 vaccine in children below 5 years of age in Germany (CoVacU5): a retrospective cohort study
Moor, Jeanne
Toepfner, Nicole
von Meissner, Wolfgang C. G.
Berner, Reinhard
Moor, Matthias B.
Kublickiene, Karolina
Strumann, Christoph
Chao, Cho-Ming
BIOLOGY OF SEX DIFFERENCES, 2024, 15 (01)
[24] Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study
Tartof, Sara Y.
Slezak, Jeff M.
Puzniak, Laura
Hong, Vennis
Xie, Fagen
Ackerson, Bradley K.
Valluri, Srinivas R.
Jodar, Luis
McLaughlin, John M.
LANCET RESPIRATORY MEDICINE, 2022, 10 (07) : 689 - 699
[25] BNT162b2 mRNA Vaccination Against COVID-19 is Associated With a Decreased Likelihood of Multisystem Inflammatory Syndrome in Children Aged 5-18 Years-United States, July 2021-April 2022
Zambrano, Laura D.
Newhams, Margaret M.
Olson, Samantha M.
Halasa, Natasha B.
Price, Ashley M.
Orzel, Amber O.
Young, Cameron C.
Boom, Julie A.
Sahni, Leila C.
Maddux, Aline B.
Bline, Katherine E.
Kamidani, Satoshi
Tarquinio, Keiko M.
Chiotos, Kathleen
Schuster, Jennifer E.
Cullimore, Melissa L.
Heidemann, Sabrina M.
Hobbs, Charlotte, V
Nofziger, Ryan A.
Pannaraj, Pia S.
Cameron, Melissa A.
Walker, Tracie C.
Schwartz, Stephanie P.
Michelson, Kelly N.
Coates, Bria M.
Flori, Heidi R.
Mack, Elizabeth H.
Smallcomb, Laura
Gertz, Shira J.
Bhumbra, Samina S.
Bradford, Tamara T.
Levy, Emily R.
Kong, Michele
Irby, Katherine
Cvijanovich, Natalie Z.
Zinter, Matt S.
Bowens, Cindy
Crandall, Hillary
Hume, Janet R.
Patel, Manish M.
Campbell, Angela P.
Randolph, Adrienne G.
CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) : E90 - E100
[26] Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: A test-negative design case-control study
Cerqueira-Silva, Thiago
Shah, Syed Ahmar
Robertson, Chris
Sanchez, Mauro
Katikireddi, Srinivasa Vittal
Oliveira, Vinicius de Araujo
Paixao, Enny S.
Rudan, Igor
Bertoldo Junior, Juracy
Penna, Gerson O.
Pearce, Neil
Werneck, Guilherme Loureiro
Barreto, Mauricio L.
Boaventura, Viviane S.
Sheikh, Aziz
Barral-Netto, Manoel
PLOS MEDICINE, 2023, 20 (01)
[27] Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study
Tartof, Sara Y.
Slezak, Jeff M.
Puzniak, Laura
Hong, Vennis
Frankland, Timothy B.
Ackerson, Bradley K.
Xie, Fagen
Takhar, Harpreet
Ogun, Oluwaseye A.
Simmons, Sarah
Zamparo, Joann M.
Valluri, Srinivas R.
Jodar, Luis
Mclaughlin, John M.
LANCET RESPIRATORY MEDICINE, 2023, 11 (12) : 1089 - 1100
[28] Effectiveness of mRNA BNT162b2 and inactivated CoronaVac vaccines against severe COVID-19 outcomes among non-hospitalised children aged 1-3 years with SARS-CoV-2 Omicron infection
Wong, Carlos K. H.
Lau, Kristy T. K.
Au, Ivan C. H.
Lau, Eric H. Y.
Cowling, Benjamin J.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2024, 63 (03)
[29] COVID-19 mRNA BNT162b2 vaccine safety and B-cell and T-cell reactogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS TS)- preliminary study
Ludwikowska, Kamila M.
Popiel, Aneta
Matkowska-Kocjan, Agnieszka
Olbromski, Mateusz J.
Biela, Mateusz
Wojcik, Marta
Szenborn, Filip
Wielgos, Katarzyna
Pielka-Markiewicz, Ewa
Zaryczanski, Janusz
Kursa, Miron B.
Szenborn, Leszek
VACCINE, 2023, 41 (13) : 2289 - 2299
[30] Longitudinal safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in children aged 4-11 years with juvenile-onset autoimmune inflammatory rheumatic diseases: A prospective multicenter study
Eviatar, Tali
Ziv, Amit
Oved, Amir
Miller-Barmak, Adi
Pappo, Adi
Livny, Ruth
Amarilyo, Gil
Aviel, Yonatan Butbul
Naor, Rinat
Pel, Sara
Furer, Victoria
Elkayam, Ori
Uziel, Yosef
Heshin-Bekenstein, Merav
VACCINE, 2024, 42 (26)

← 1 2 3 4 →